The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat distribution, with greater weight loss linked to better outcomes, a study ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...